 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Apr 30 Calls Today's Calls |
| Call Details | |||
| Indevus Pharmaceuticals, Inc. Earnings Conference Call (Q2 2008) Wed, Apr 30, 2008, 9:00 am Eastern
| |||
| About Indevus Pharmaceuticals, Inc. (NasdaqGM:IDEV) | |||
| Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology in the United States. The company’s approved products consist of SANCTURA, a muscarinic receptor antagonist, and SANCTURA XR for the treatment of overactive bladder that are co-promoted with its partner Allergan, Inc.; VANTAS for treating advanced prostate cancer, SUPPRELIN LA for central precocious puberty, and DELATESTRYL for the treatment of hypogonadism. Its urology and endocrinology development portfolio contains multiple compounds, which comprise NEBIDO for male hypogonadism; VALSTAR for bladder cancer; PRO 2000 for the prevention of infection by HIV and other sexually-transmitted diseases; the octreotide implant for acromegaly; and a biodegradable ureteral stent for the treatment of kidney stones. Indevus Pharmaceuticals also outlicenses the development and commercialization of various compounds comprising pagoclone for stuttering; ALKS 27 for chronic obstructive pulmonary disease, which it jointly develops with Alkermes, Inc.; aminocandin for systemic fungal infections for which, the company licensed the know-how to Novexel S.A.; and IP 751 for pain and inflammation for which, it licensed worldwide rights to Cervelo Pharmaceuticals, Inc. The company was founded in 1988 and is headquartered in Lexington, Massachusetts. | |||
More Info: | |||
